There are currently 980 clinical trials in Tampa, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Moffitt Cancer Center, University of South Florida, H. Lee Moffitt Cancer Center and Research Institute and Tampa General Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum
NCT05964413
Recruiting
A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate efficacy and safety of vilobelimab in the treatment of ulcerative pyoderma gangrenosum
Gender:
All
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: ForCare Clinical Research, Tampa, Florida
Conditions: Pyoderma Gangrenosum
Register for Updates
ProVIDE II Bridging Study
NCT06236802
Recruiting
The purpose of the ProVIDE II Bridging Study is to evaluate the performance of the Generation II delivery system when deploying the ProVee expander in subjects with symptomatic urinary obstruction secondary to BPH.
Gender:
Male
Ages:
45 years and above
Trial Updated:
05/16/2024
Locations: Florida Urology Partners, LLP, Tampa, Florida
Conditions: BPH With Symptomatic Lower Urinary Tract Symptoms
Register for Updates
Myositis Interstitial Lung Disease Nintedanib Trial
NCT05799755
Recruiting
This research study will evaluate safety and how well the study drug, nintedanib improve symptoms in participants with myositis associated interstitial lung disease (MA-ILD). Interstitial lung disease is a disorder caused by the abnormal accumulation of cells structures between air sacs of the lungs resulting in thickening, stiffness and scarring of the tissues of the lung. This study will enroll a total of 134 participants across 15 clinical sites located in the United States. A subset of part... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/15/2024
Locations: University of South Florida, Tampa, Florida
Conditions: Myositis Associated Interstitial Lund Disease (MA-ILD)
Register for Updates
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
NCT04065399
Recruiting
Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 3 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, and tolerability of revumenib.
Gender:
All
Ages:
30 days and above
Trial Updated:
05/15/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
Register for Updates
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
NCT05080764
Recruiting
The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) for the medication Ameluz® performed with the PDT-lamp BF-RhodoLED® in comparison to the respective placebo treatment for moderate to severe Acne vulgaris.
Gender:
All
Ages:
16 years and above
Trial Updated:
05/15/2024
Locations: ForCare Clinical Research, Tampa, Florida
Conditions: Acne Vulgaris
Register for Updates
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT05768139
Recruiting
Study STX-478-101 is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 in participants with advanced solid tumors with certain mutations. Part 1 will evaluate STX-478 as monotherapy in participants with advanced solid tumors and breast cancer; Part 2 will evaluate STX-478 therapy as combination therapy with fulvestrant in participants with breast cancer. Each study part will include a 28-day screen... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/15/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Breast Cancer, Gynecologic Cancer, HNSCC, Solid Tumors, Adult
Register for Updates
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
NCT06088199
Recruiting
The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
05/15/2024
Locations: University of South Florida, Tampa, Florida
Conditions: Plaque Psoriasis
Register for Updates
ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC
NCT04032847
Recruiting
This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterise the safety and clinical activity autologous clonal neoantigen reactive T cells (cNeT) administered intravenously in adults with advanced non-small cell lung cancer (NSCLC).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/15/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Advanced Non Small Cell Lung Cancer
Register for Updates
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
NCT04042701
Recruiting
This two-part study will include a dose escalation part to determine the recommended dose for expansion of DS8201a and pembrolizumab and a dose expansion part to evaluate efficacy, safety, and tolerability of the combination.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Moffit Cancer Center, Tampa, Florida
Conditions: Breast Cancer, Non-small Cell Lung Carcinoma
Register for Updates
Home-Based Respiratory Muscle Strength Training Program for Individuals With Post-COVID-19 Persistent Dyspnea
NCT06091280
Recruiting
To evaluate the extent to which a 12-week respiratory rehabilitation program consisting of inspiratory and expiratory breathing exercises compared to expiratory breathing exercises alone will help to improve shortness of breath, respiratory symptoms, breathing function, distance walked, and quality of life in those who are experiencing persistent shortness of breath after having had COVID-19. Measurements will take place at the beginning, 6 weeks, and at 12 weeks in the study.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: University of South Florida, Tampa, Florida
Conditions: Post-COVID-19 Syndrome, Dyspnea
Register for Updates
A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma
NCT05705531
Recruiting
This study assesses how blood cell growth patterns (clonal hematopoiesis), relates to heart health or cardiovascular disease (CVD) after treatment in patients with Hodgkin lymphoma. In some patients, cancer treatment at a young age may lead to later complications, including problems with heart health. Checking for blood cell growth patterns called therapy-related clonal hematopoiesis (t-CH) can help predict who might be at risk for heart health problems after Hodgkin lymphoma treatment. If docto... Read More
Gender:
All
Ages:
Between 7 years and 40 years
Trial Updated:
05/14/2024
Locations: Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida
Conditions: Hodgkin Lymphoma, Cardiovascular Disorder, Clonal Hematopoiesis
Register for Updates
A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for Primary Central Nervous System Tumors
NCT04939597
Recruiting
This phase III trial compares memantine to usual treatment in treating patients with primary central nervous system tumors. Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving memantine may make a difference in cognitive function (attention, memory, or other thought processes) in children and adolescents receiving brain radiation therapy to treat a primary central nervous system tumors.
Gender:
All
Ages:
Between 4 years and 17 years
Trial Updated:
05/14/2024
Locations: Tampa General Hospital, Tampa, Florida +1 locations
Conditions: Central Nervous System Carcinoma
Register for Updates